Cargando…

Comprehensive Analysis and Risk Identification of Pulmonary Cryptococcosis in Non-HIV Patients

Pulmonary cryptococcosis in the non-human immunodeficiency virus-infected population is uncommon. We aimed to explore the relevance between clinical presentations, radiological findings, and comorbidities and identify the outcome predictors. A total of 321 patients at Taichung Veterans General Hospi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Chun, Yang, Tsung-Ying, Chan, Ming-Cheng, Hsu, Kuo-Hsuan, Huang, Yen-Hsiang, Tseng, Jeng-Sen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8399630/ https://www.ncbi.nlm.nih.gov/pubmed/34436197 http://dx.doi.org/10.3390/jof7080657

Ejemplares similares

Cryptic pulmonary cryptococcosis: An atypical presentation of pulmonary cryptococcosis in a HIV-infected patient
por: Maepa, H M
Publicado: (2019)

The Role of Neutrophil-to-Lymphocyte Ratio in Advanced EGFR-Mutant NSCLC Patients Treated with First-Line Osimertinib
por: Chen, Kuan-Chih, et al.
Publicado: (2023)

Pulmonary Cryptococcosis
por: Howard-Jones, Annaleise R., et al.
Publicado: (2022)

Radiological characteristics of pulmonary cryptococcosis in HIV-infected patients
por: Hu, Zhiliang, et al.
Publicado: (2017)

Miliary pulmonary cryptococcosis
por: Kelly, Shane, et al.
Publicado: (2014)

Cutaneous and pulmonary cryptococcosis()()
por: Markman, Deborah Lucena, et al.
Publicado: (2020)

Clinicopathological features of isolated pulmonary cryptococcosis in HIV-negative patients
por: Wu, Huan-Huan, et al.
Publicado: (2020)

Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy
por: Ou, Wei-Fan, et al.
Publicado: (2023)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Pulmonary cryptococcosis: An unusual presentation
por: Babu, Anand K., et al.
Publicado: (2013)

Pulmonary Cryptococcosis Complicated by Sarcoidosis
por: Nureki, Shin-ichi, et al.
Publicado: (2017)

Integrated therapy for HIV and cryptococcosis
por: Srichatrapimuk, Sirawat, et al.
Publicado: (2016)

Retrospective analysis of pulmonary cryptococcosis and extrapulmonary cryptococcosis in a chinese tertiary hospital
por: Shi, Jiejun, et al.
Publicado: (2023)

Intercalated Treatment Following Rebiopsy Is Associated with a Shorter Progression-Free Survival of Osimertinib Treatment
por: Tseng, Jeng-Sen, et al.
Publicado: (2018)

ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
por: Chang, Gee-Chen, et al.
Publicado: (2020)

Clinical impact of advanced chronic kidney disease in patients with non-HIV pulmonary cryptococcosis
por: Tashiro, Hiroki, et al.
Publicado: (2020)

Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)

PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2022)

The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Pulmonary cryptococcosis induces chitinase in the rat
por: Vicencio, Alfin G, et al.
Publicado: (2008)

Isolated pulmonary cryptococcosis in an immunocompetent boy
por: Bauer, Siegfried, et al.
Publicado: (2010)

Pulmonary Cryptococcosis Mimicking Lung Cancer
por: Eremiev, Simeon, et al.
Publicado: (2022)

Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant)
por: Wu, Jia-Jun, et al.
Publicado: (2022)

Cryptococcosis in a patient with HIV infection
por: Benea, Vasile, et al.
Publicado: (2013)

HIV/AIDS and Cryptococcosis in Costa Rica
por: Villalobos, Juan, et al.
Publicado: (2017)

Disseminated Cryptococcosis in a Non-HIV Patient in Singapore
por: See, Jonathan, et al.
Publicado: (2019)

Immune reconstitution inflammatory syndrome, with pulmonary and neurological cryptococcosis, in an HIV-negative patient
por: Queiroz, Rodolfo Mendes, et al.
Publicado: (2016)

Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
por: Lee, Po-Hsin, et al.
Publicado: (2021)

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Pulmonary cryptococcosis presenting with a large cavity
por: Morita, Satoru, et al.
Publicado: (2014)

Pulmonary cryptococcosis with cryptococcal meningitis in an immunocompetent host
por: Panigrahi, Manoj Kumar, et al.
Publicado: (2014)

PR3-ANCA-positive Pulmonary Cryptococcosis
por: Goto, Akihiko, et al.
Publicado: (2017)

Clinical features and radiological characteristics of pulmonary cryptococcosis
por: Deng, Hui, et al.
Publicado: (2018)

Characteristics of pulmonary cryptococcosis in patients with rheumatoid arthritis
por: Hosoda, Chiaki, et al.
Publicado: (2021)

Clinicoradiological Features of Pulmonary Cryptococcosis in Immunocompetent Patients
Publicado: (2023)

Pulmonary Cryptococcosis: Imaging Findings in 23 Non-AIDS Patients
por: Song, Kyoung Doo, et al.
Publicado: (2010)

Publisher Correction: The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
por: Huang, Yen-Hsiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ap7vsuhms0tb70evgvuqrbr8v9